Objective: To determine the clinical and performance related utility of hematological and iron-related screening in elite athletes.
Results: Eight female athletes (4.6%) had clinically relevant abnormal results, 6 with an obvious explanation on clinical history and examination and 1 who was diagnosed with hemochromatosis following genetic testing. Eighty-nine (51.1%) female athletes had abnormal results that were not associated with obvious clinical signs or symptoms. Twenty-seven female athletes had a serum ferritin less than 30 ng/mL and were placed on iron supplementation. In male athletes, 5 cases had screening abnormalities that were associated with illness or other factors identified during the clinical consultations. Nonclinically significant abnormalities in males were generally minor reductions in hemoglobin and/or hematocrit or minor alterations in red cell parameters. Five male athletes had a serum ferritin less than 30 ng/mL and were placed on iron supplementation.
Conclusion:
Screening for hematological and iron-related abnormalities in male athletes has a very low yield. Due to the critical nature of the effects of anemia and low serum ferritin on some aspects of performance, it is reasonable to perform a full blood count and a serum ferritin on male athletes entering an elite training program. Further testing should be performed on clinical grounds. In females, the yield is greater. Again, it is reasonable to perform a full blood count and a serum ferritin on female athletes entering an elite training program. In view of their greater risk of iron depletion and to assess the effect of increased training inherent in elite programs, this could be repeated at 6-month intervals, or an isolated measurement of serum ferritin could be performed. Further testing should be performed on clinical grounds. S omewhat surprisingly, there is a paucity of prospective studies related to the usefulness of screening of hematological and iron-related variables in elite athlete populations. Hematological and iron-related variables have been documented in athletes participating in a wide variety of sports, 1 but the clinical and performance-related significance of screening results in elite populations has not been documented.
In 2 large studies of preparticipation health screening, blood analysis was not mentioned and presumably not included in the evaluation. 2, 3 Only 1 study, conducted retrospectively in 1067 college athletes, assessed the value of screening for hematological variables. The authors measured white blood cell count (WCC), hemoglobin, mean corpuscular volume (MCV), and platelet count in both males and females and concluded that the only useful test was that for hemoglobin. 4 The aspect of hematological and biochemical screening that is most justifiable is that of anemia. In athletes, as in the general population, anemia is most frequently associated with iron deficiency. The prevalence of iron deficiency anemia is quite low (approximately 3%) and is similar in athletes and untrained individuals. 5 The functional consequences of anemia have often been described and include reductions in endurance and maximal work capacity, 6 and there is no doubt about improvements in work performance in anemic athletes following correction of an iron deficit. Characterization of the type of anemia requires assessment of red cell parameters; therefore, rather than a simple hemoglobin measurement, a full (or complete) blood count is often performed during screening.
The assessment of iron status is a more vexed issue. The level of serum ferritin at which supplementation should be commenced is controversial. A level of 12 ug/L has been correlated with lack of marrow iron stores. 7 Data presented below suggest that less than 16 or 20 ug/L may be an appropriate cutoff, and common patterns of supplementation suggest 35 ug/L. 8 Some indication of the extent of the potential value of screening in females is provided by prevalence data from a group of 37,188 healthy females. 9 In the age group 12 to 32 years, which covers most of the athletic population, approximately 7% were in the lowest 2.5% of ferritin values and therefore below the level typically described as normal. Fourteen percent of menstruating women in this study had a serum ferritin <15ug/L. Of greater relevance to the athletic population, Fogelholm 5 summarized the results of 6 studies that assessed the prevalence of storage iron depletion, based on cutoff values of 12 to 20 ug/L for serum ferritin, in athletic and control females. The pooled mean prevalences of storage iron depletion were 37% in athletes and 23% in controls. In view of the relatively large number of female athletes identified with storage iron deficiency, it appears that there is some justification, at least in females, for screening for serum ferritin in the athletic population. This would be especially true if storage iron deficiency was shown to have a negative effect on performance. There are some early indications that this is indeed the case.
The clinical value of serum ferritin tests in endurance athletes was reviewed in 1997 by Garza et al. 10 The authors correctly concluded, based on evidence available at the time, that "the literature does not justify routine measurement of ferritin as an independent marker of endurance performance in athletes." This was based on data that, in the main, indicated that in the absence of anemia, low serum ferritin was not associated with reduced endurance performance.
Recent evidence calls this conclusion into question. Hinton et al, 11 in a double-blind, placebo-controlled trial, investigated the effect of iron supplementation (100 mg ferrous sulfate per day) in 42 iron-depleted (serum ferritin <16 µg/L), nonanemic (hemoglobin >12 g/dL) women. The performance measure was time to completion of a 15-km cycle ergometer test. Following 6 weeks of supplementation or placebo and a training program, serum ferritin increased in the supplemented group, and the decrease in test time was significantly greater in the supplemented subjects. The authors indicated that both changes in hemoglobin and ferritin contributed to the improvement in performance. This clouds the relationship between low ferritin levels and performance and raises the issue of functional anemia in which the hemoglobin level, while within normal limits, is suboptimal for the particular athlete and can be corrected to the true normal level by iron supplementation. The increase in hemoglobin rather than the correction of low iron stores is hypothesized to be the factor that explains improvements in performance.
Freidmann et al, 12 in a double-blind, placebo-controlled trial, investigated the effect of iron supplementation (100 mg elemental iron, twice a day) in 40 young elite athletes with iron depletion (serum ferritin <20 µg/L) and normal hemoglobin (hemoglobin >13.5 g/dL in males and >11.7 in females). The athletes were randomly assigned to placebo or iron supplementation for a period of 12 weeks. At the end of the trial, ferritin levels were within the normal range in the iron-treated group, with a significant mean increase of 20 ug/L. There were no other significant changes in any hematological variable in either group. The iron supplementation group demonstrated significant changes in VO 2max and in oxygen consumption in a maximal accumulated oxygen deficit test. This suggests that in young elite athletes with low serum ferritin and normal hemoglobin concentration, iron supplementation leads to an increase in aerobic capacity and possibly endurance performance.
Similar evidence has been presented in untrained female subjects in a study by Brownlie et al. 13 In a double-blind, placebo-controlled trial, they investigated the effect of iron supplementation (50 mg ferrous sulfate, 8 mg elemental iron, twice daily) in 41 active, untrained, iron-depleted (serum ferritin <16 µg/mL), nonanemic (hemoglobin >12 g/dL) women on the response to a training program. All subjects trained on cycle ergometers 5 days per week for 4 weeks. Results were stratified based on the level of soluble transferrin receptor (sTfR), a parameter that is reported to indicate tissue iron status. Changes in iron status (serum ferritin, iron and soluble transferrin receptor, and transferrin saturation) were significantly associated with changes in VO 2max among subjects in the high stratum for sTfR but not among subjects in the low stratum.
Brutsaert et al, 14 in a double-blind, placebo-controlled trial, studied the effect of iron supplementation (10 mg elemental iron as ferrous sulfate, twice daily for 6 weeks) in 20 active, untrained, iron-depleted (serum ferritin <20 µg/mL), nonanemic (hemoglobin >11 g/dL) women on fatigue resistance during dynamic knee extensor exercise. A protocol integrating 2-second to 3-second maximal voluntary static contractions of dynamic knee extension was used to assess fatigue. After 6 weeks of supplementation, serum iron and transferrin saturation significantly increased in the iron group. sTfR concentrations increased significantly in the placebo group but not in the iron group. In the iron group, the maximal voluntary static contraction at the sixth minute of the fatigue protocol and at the end of the protocol were significantly higher (15% and 27%, respectively).
These studies suggest that, from a performance point of view, it may be appropriate to maintain serum ferritin levels in athletes at a level of at least 16 or 20 ug/mL, and therefore, that this parameter should be included in routine screening. However, there are complicating findings in these studies that mandate further research evidence before a definitive statement can be made.
The remainder of this article details a prospective study of the clinical and, in light of the aforementioned studies, potential performance-related utility of the full blood count and iron studies (serum iron, ferritin, transferrin, and percent transferrin saturation) in a mixed group of elite athletes.
METHODS
This study was approved by the Ethics Committee of the Australian Institute of Sport (AIS). All procedures conformed to the National Health and Medical Research Council guidelines for experimentation with human subjects, and all subjects gave their informed written consent before participation.
All athletes (120 males and 174 females) presenting at the Sports Science/Sports Medicine Center at the AIS for routine screening during a 2-year period were entered into the study. They underwent a standard medical examination by specialist sports physicians, and at its conclusion, blood (12 mL) was drawn under aseptic technique from a vein in the cubital fossa. Blood was drawn immediately following the assumption of the recumbent position and was transported immediately to an adjacent hematology laboratory, where analysis was performed on the same day.
Due to training demands and, on some occasions, the demand for screening large numbers of athletes in short time periods, the timing of blood collection was not standardized in relation to periods of training and time of day. Therefore, parameters potentially affected by training (WCC, platelets) and diurnal variation (serum iron) may have been perturbed from true baseline levels.
The hematology analyzers used in this study (Advia 120, Bayer Diagnostics, Tarrytown, using Bayer reagents) are capable of measuring a large number of variables in a full blood count, but only a clinically relevant selection was included in this study: WCC, red blood cell count (RCC), hemoglobin, hematocrit, MCV, mean cell hemoglobin concentration (MCHC), platelet count, and percent hypochromic red cells. The following iron related parameters were measured on a Hitachi 911 analyzer (Roche Diagnostics, Indianapolis, IN, using Roche reagents): iron, ferritin, transferrin, and percent transferrin saturation.
Normal ranges were those of the AIS laboratory; however, for serum ferritin, 3 lower limits of significance were used. A level of 12 ug/L, which has been correlated with lack of marrow iron stores, 7 was defined as the absolute lower limit. A level of 20 ug/L was felt to be significant in performance terms as there is evidence that iron supplementation of nonanemic female and male athletes with serum ferritin less than 20 has a positive effect on performance. [11] [12] [13] [14] A level of less than 30 ug/L is used at the AIS as an indication for iron supplementation based on sensitivity and specificity data published by Mast et al, 15 common patterns of supplementation elsewhere, 8 and preliminary data from a study currently in progress in which the relationship between serum ferritin and sTfR in elite athletes is being studied.
Athletes were divided into 3 groups dependent upon their results: all results normal, results abnormal with no clinically obvious explanation, and results abnormal with an explanation apparent from history and clinical examination. The results of those in the third group were excluded from the statistical analysis. The significance of abnormal results was assessed by follow-up consultations with the athletes. Due to differing normal ranges for some parameters, results for males and females were analyzed separately.
Simple descriptive statistics (mean, confidence intervals, standard deviation, median, minimum, maximum, and range) were performed on Statistica, version 5, Statsoft, Tulsa.
RESULTS

Male Athletes
All male athletes were scholarship holders of the AIS and participated at the elite level of competition. They ranged in age from 15 to 31 years (mean, 20 years).
Sports represented, numbers in each sport, and percentages of those screened who had abnormal results and of those who were placed on iron supplementation are detailed in Table 1 .
One hundred twenty male athletes had a full blood count and iron studies, and due to an undetermined laboratory error, 1 athlete had only the full blood count performed. Statistical analysis of group parameters is detailed in Table 2 .
Five male athletes had abnormal results with a clinical explanation. The first had a raised serum iron (37.7 umol/L; normal range, 10.6-28.3) and percent transferrin saturation (54; normal range, 15-50) related to concurrent intake of iron supplements. The second had serum iron (8 umol/L) and transferrin saturation (11%) outside the normal range in association with a relatively high serum ferritin (210.7 ng/mL). These findings, typical of an acute phase response, were associated with a gastrointestinal infection, presumably viral. At followup, 5 days after the initial test, serum iron was 8 umol/L, transferrin saturation was 29%, and serum ferritin had decreased to 99 ng/mL. The third, a rugby league football player, had serum iron of 9.7 µmol/L and transferrin saturation of 13%. These findings were associated with a trace of blood and 1+ glycosuria on dipstick urinalysis associated with a normal serum glucose. On microscopy, no red cells were seen, and culture was negative. He was asymptomatic and normal on clinical examination. The athlete was asked to have these findings followed up by his usual general practitioner. He declined further investigation but was asymptomatic and playing at the level 1 year after the initial screening. The fourth had a raised white cell count (11.88 × 10 9 /L) in association with an ocular infection. The fifth of clinical significance had an MCV of 78.6 fl associated with low ferritin (21.5 ng/mL) and low transferrin saturation (11%). This athlete was not anemic, and the other iron-related parameters were normal. He was symptomatic with a lower respiratory infection. When his subsequent course was investigated, it was found that 9 months later, at the time of another respiratory infection, he was found to have iron deficiency anemia with a hemoglobin of 11.8, hypochromic, microcytic red cells, serum ferritin 5 ng/mL, serum iron 5.3 µmol/L, and low transferrin saturation (7%). After gastroscopy, colonoscopy, and gastric and duodenal biopsy, the final diagnosis was ulcerative reflux esophagitis exacerbated by the use of nonsteroidal anti-inflammatory drugs.
Twelve athletes were technically anemic with hemoglobin levels below the lower limit of normal (14 g/dL). All were in the range 13.3 to 13.9 g/dL. Ten of these athletes had a hematocrit below the lower limit of normal (0.41). All were in the range 0.37 to 0.40. In 1 of these cases, the RCC was reduced at 4.37 × 10 12 /L (normal range, 4.50-6.50 × 10 12 /L) and the MCHC was increased, and in another, the MCV was low (76.2 fl) and the serum iron was increased (30.1 umol/L).
Eleven athletes had a hematocrit below the lower limit of normal (0.41). All were in the range 0.39 to 0.40. In 9 cases, hemoglobin was normal, and in 2 there were minor reductions (both 13.8g/dL). In all but 1 case (noted above) in which the hemoglobin and/or hematocrit were below normal, the red cells were normochromic and normocytic. In all but 1 case, in which iron studies were not done, iron studies were normal.
Six athletes had raised MCHC as an isolated finding. One athlete had a raised MCHC (37.0 g/dL) associated with a mild elevation of platelets (409 × 10 9 /L) and another (36.8 g/dL) associated with a hematocrit of 0.40. One athlete had a marginally increased MCV (96.3; normal range, 80-96 fl) as an isolated finding. Two had reduced MCVs (78.5 and 78.6) as isolated findings. Four athletes had reduced MCVs in association with other abnormalities. One athlete had a raised WCC in association with a reduced RCC and hematocrit. Two athletes had a reduced WCCs (3.97 and 3.89; normal range, 4-11 × 10 9/ L) as isolated findings. The other case with a reduced MCV is discussed above. Three athletes had reduced transferrin levels that were not considered to be clinically significant.
Three athletes had a serum ferritin less than 30 ng/mL (16.4, 24.1, and 27.9 ng/mL) as an isolated finding. This is not technically abnormal but is below the AIS threshold for iron supplementation and was therefore significant in our context. Two other cases of serum ferritin less than 30 ng/mL were found. One is noted above, and the other, with a serum ferritin of 26 ng/mL, was associated with a hemoglobin of 13.8 g/dL and a hematocrit of 0.39. Two athletes had a raised serum iron (30.1 and 37.9 umol/L; normal range, 10.6-28.3) as an isolated finding. Nine athletes had increased serum iron (range, 31.1-42.7 umol/L) associated with increased transferrin saturations (range, 51%-102%) and normal serum ferritin. None were using iron supplements. Five of these cases were tested on the same day, and repeat tests several days later were normal. A laboratory error is the most likely explanation for this cluster of abnormal results. Two of the others had repeat tests that were normal, and 2 athletes were referred to their general practitioners for follow-up. Their results are unknown.
Female Athletes
All female athletes were scholarship holders of the AIS and participated at the elite level of competition. They ranged in age from 11 to 34 years, with a mean of 22 years.
Sports represented, numbers in each sport, and percentages of those screened who had abnormal results and of those who were placed on iron supplementation are detailed in Table 3 . Statistical analysis of group parameters is detailed in Table 4 .
Eight female athletes (4.6%) had clinically relevant abnormal results-6 with an obvious explanation, 1 who was normal on further testing, and 1 who was subsequently shown to the homozygous for the C282Y mutation for hemochromatosis. Three athletes had raised WCC related to upper respiratory tract infections at the time of screening. One athlete had a low transferrin saturation (14%) and low normal serum iron (7.4 umol/L) in association with an upper respiratory infection. This is consistent with an acute phase response. Three athletes had elevations in both serum iron and transferrin saturation, 1 of these with a low normal serum ferritin. One of these athletes was using iron supplementation, 1 was normal on follow-up testing, and 1 was found to have hemochromatosis.
Eighty-nine (51.1%) female athletes had abnormal results that were not associated with obvious clinical signs or symptoms. Five athletes had isolated raised WCCs (11.30, 11.74, 12.58, 12.63, and 14.38 × 10 9 /L). None of these athletes had symptoms or signs of infection. Six athletes had isolated raised platelet counts (range, 404-496 × 10 9 /L). No symptoms or signs were demonstrated in these athletes. Fourteen athletes had isolated increases in serum iron (range, 26.1-37.0 umol/L; normal range, 6.6-26 umol/L). One athlete had a raised serum iron accompanied by a reduced MCV. Three athletes had a raised serum iron with a raised transferrin saturation. In 1 case, /L, respectively). One had reduced hemoglobin (11.5 g/dL) and hematocrit (0.35). Twenty-seven athletes had serum ferritin less than 30 ng/mL. In 14 cases, this was an isolated abnormality (range, 16.3-29.8 ng/mL).
The others presented a mixture of generally minor abnormalities. Athlete 1 had ferritin 18.1 ng/mL, iron increased, transferrin saturation increased, hematocrit 0.36 (normal range, 0.37-0.47). Athlete 2 had ferritin 19.3 ng/mL, iron increased, hematocrit 0.36. Athlete 3 had ferritin 28.4 ng/mL, MCV 79.5 (normal range, 80-96 fl). Athlete 4 had ferritin 13.3 ng/mL, hematocrit 0.36. Athlete 5 had ferritin 19.8 ng/mL, transferrin saturation 12%, MCHC 36.1 g/dL. Athlete 6 had ferritin 21.7 ng/mL, transferrin saturation 11%, hematocrit 0.34, hemoglobin 11.8 (normal range, 12-16 g/dL). Athlete 7 had ferritin 18.8 ng/mL, transferrin saturation 8%. Athlete 8 had ferritin 18.4 ng/mL, hematocrit 0.35. Athlete 9 had ferritin 20.8 ng/mL, transferrin saturation 13%, hematocrit 0.36. Athlete 10 had ferritin 17.8 ng/mL, transferrin saturation 14%. Athlete 11 had ferritin 9.9 ng/mL, serum iron 26.8. Athlete 12 had ferritin 25.7 ng/mL, transferrin saturation 12%. Athlete 13 had ferritin 15.4 ng/mL, transferrin saturation 13%, hematocrit 0.36, increased sTfR.
One athlete had a low hemoglobin (11.5g/dL) and hematocrit (0.35). The red cells were normochromic and normocytic, and iron studies were normal.
DISCUSSION
Male Athletes
Five cases were identified in which screening abnormalities were associated with illness or other factors that explained the abnormalities. In 3 cases, hematological screening did not contribute clinically useful data as the abnormalities would have been expected based on the history and examination. In the other 2, the case of the asymptomatic slowly developing iron deficiency and of the football player who refused follow-up, hematological and iron-related screening uncovered clinically useful information.
Of the other male athletes with hematological abnormalities, most had minor reductions in hemoglobin and/or hematocrit with normocytic, normochromic red cells and normal iron studies. The differential diagnosis of normocytic anemia is wide, with potential causes including acute blood loss, hemolysis, disorders of the red cell membrane such as spherocytosis, red cell enzyme deficiencies, myeloproliferative disease, the anemia of chronic disease, and plasma volume expansion. 16 No history of relevant diseases was found in these athletes, and while chronic footstrike hemolysis cannot be excluded from the history or blood tests performed, it was concluded that the most likely cause was dilutional or sports anemia. This is a normal adaptation to repeated exercise, and treatment is not required. 17 As such, screening that leads to its detection is not useful. It should be noted that dilutional anemia is a diagnosis of exclusion; however, the extent of investigation of a very mild normochromic, normocytic anemia in healthy athletes who are asymptomatic and normal on physical examination and who have other hematological and ironrelated parameters that are normal is controversial. Some of the minor abnormalities may also have been related to the statistical possibility of being outside the defined normal range but still being part of the normal population.
Isolated abnormalities in MCHC and MCV in the absence of clinical findings were not thought to be of clinical relevance and were not specifically investigated.
One of the athletes with the isolated elevation in serum iron that was associated with a high normal transferrin saturation was referred to his general practitioner for repeat testing. This was normal. He was not using iron supplements at the time of screening.
The athletes with abnormalities in WCC were clinically normal, and no follow-up was indicated.
Five sets of abnormal serum iron and transferrin saturation results appear to be the result of laboratory error.
In summary, the screening blood tests carried out on this group of elite male athletes found only 2 sets of abnormalities of clinical significance that could not have been suspected from clinical history and examination. Five athletes with a serum ferritin less than 30 ng/mL satisfied our criteria for iron supplementation. These were the only cases in which a change in athlete management was made based solely on blood test results.
Female Athletes
Six cases were identified in which screening abnormalities were associated with illness or other factors that explained the abnormalities. In each case, hematological screening would not have been useful as the abnormalities would have been expected based on the history and examination. Two others required further investigation.
Twenty-seven athletes were identified as candidates for iron supplementation (ferritin <30 ng/mL). One of these satisfied the criterion for absent iron stores (serum ferritin <12 ng/mL). Fortuitously, up to 3 indictors of functional iron deficiency (increase in sTfR 18, 19 ) and/or impaired red cell hemoglobinization (reticulocyte hemoglobin <28 pg and >5% hypochromic red cells) 20 were available for these subjects. In 19 athletes, all 3 parameters were normal. In 2, serum sTfR was elevated. In 4, sTfR was not measured, but the other parameters were normal. In 1, reticulocyte hemoglobin was not measured, but the other parameters were normal; in the other, only percent hypochromic red cells was measured, and this was normal. It is therefore proposed that 25 of these 27 athletes had low iron stores without iron deficient erythropoiesis and that the 2 with raised sTfR had iron-deficient erythropoiesis.
Two female athletes had a reduced hematocrit (both 0.34), hemoglobin (11 and 11.8g/dL), and RCC (3.76 and 3.67 × 10 12 /L, respectively) and were therefore technically anemic. Both had normochromic, normocytic red cells, no evidence of impaired red cell hemoglobinization, and normal iron studies. There was no history of disorders associated with normochromic, normocytic anemia, and no further investigation was felt warranted. The likely explanations are dilutional or sports anemia or a statistically abnormal result in a normal subject.
One athlete had a low hemoglobin (11.5 g/dL) and hematocrit (0.35). The red cells were normochromic and normocytic, and iron studies were normal. The athlete was well, and there was no history of chronic disease. Previous investigation for a hemoglobinopathy had been normal.
The only other subjects in whom clinical follow-up was felt to be indicated were 2 athletes with a raised serum iron and transferrin saturation. On further history, 1 was using iron supplementation. Due to the possibility of early hemochromatosis, the other was retested, and after a finding of persistently elevated iron parameters, she underwent genetic analysis, which proved positive for hemochromatosis.
In summary, screening of 174 female athletes led to the detection of 1 clinical disorder and 27 athletes who were placed on iron supplementation. Of these 27, 14 had serum ferritin <20 ng/mL, which may have been impinging on some aspects of performance.
GENERAL COMMENTS
In a significant proportion of the athletes screened, the abnormalities found were isolated and close to the limits of their normal ranges. In general, they were of no clinical significance, suggesting that these abnormal results are a consequence of the usual method of definition of the normal range.
Hematological and iron-related screening of this group of athletes may underestimate the number of abnormalities that could be found in other athletic groups. Because of the elite nature of the athletes involved, one could expect that they would have been tested previously and that abnormalities identified had been corrected. Indeed, a significant number of these athletes had been previously tested at the AIS.
A number of methodological issues could impact on the accuracy of assessment of a number of the parameters used in hematological and iron-related screening. When screening large groups of athletes in short time periods, it is not always possible to test all athletes at the same time of day or standardize the relationship between training and blood collection. If this is the case, the following confounding factors should be considered.
Firstly, diurnal variation may affect some parameters. In particular, this needs to be taken into account when assessing the significance of serum iron measurements, which are typically higher in the morning. Alterations in plasma volume caused by postural changes have been well documented, 21 with plasma volume generally being greater in the supine rather than the upright position. These changes can occur rapidly, generally being complete within 20 minutes, so they may be minimized by immediate venepuncture after assuming the recumbent position. Similarly, acute changes in plasma volume leading to hemoconcentration have been demonstrated immediately after long distance running, bicycle ergometry, and maximal and submaximal swimming. 22 These may be minimized by collection of blood several hours after an exercise session or in the morning prior to training.
The acute phase response is another potential confounding factor. Among other changes, this response causes changes in iron-related parameters-namely, increased serum ferritin and decreased serum iron, transferrin, and transferrin saturation and an increase in the white blood cell count. This response has been demonstrated following ultramarathon running 23 but was not demonstrated following extended periods of training for court and field sports. 24 The presence or absence of this response in the few hours following an acute training session has not been studied, but this response could be significant in interpretation of the parameters under discussion and needs further exploration.
CONCLUSIONS
Screening for hematological and iron-related abnormalities in male athletes has a low yield. Due to the critical nature of the effects of anemia and low serum ferritin on some aspects of performance, it is reasonable to perform a full blood count and a serum ferritin on male athletes entering an elite training program. Further testing should be performed on clinical grounds.
In females, the yield is greater. Again, it is reasonable to perform a full blood count and a serum ferritin on female athletes entering an elite training program. In view of their greater risk of iron depletion and to assess the effect of increased training inherent in elite programs, this could be repeated at 6-month intervals, or an isolated measurement of serum ferritin could be performed. Further testing should be performed on clinical grounds.
